The cost–effectiveness of clopidogrel: a review by indication

Author: Schleinitz, Mark D

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 6, Number 2, April 2006 , pp. 123-130(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Clopidogrel is a thienopyridine that acts by inhibiting the adenosine diphosphate-dependent activation of platelets. It has proven efficacy in two general categories: long-term secondary prophylaxis in populations with existing vascular disease, and of limited duration following cardiovascular events or procedures. Clopidogrel may be used alone or in combination with aspirin, depending on the indication. The cost–effectiveness of clopidogrel varies with the indication, the population in which it is used, the risk of future events faced by that population and whether it is combined with aspirin. This article will review existing data on the cost–effectiveness of clopidogrel for each indication with a particular focus on these four criteria.

Keywords: antiplatelet therapy; aspirin; clopidogrel; cost–effectiveness analysis; myocardial infarction; peripheral arterial disease; secondary prophylaxis; stroke

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.6.2.123

Publication date: 2006-04-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites